The Oncologist newsletter arrived in my in-box
today. Several useful articles including one on oral anticoagulants:
Hanno Riess et al.
Direct
oral anticoagulants (DOACs) offer several advantages over traditional
anticoagulants, including ease of administration and the lack of need
for routine monitoring. However, the management of patients with an
indication for anticoagulation and concomitant cancer, who are at high
risk of thromboembolic events, presents several challenges for
administering oral therapies, particularly with regard to the risk of
nausea and vomiting. In the absence of robust data from randomized
trials and specific guidelines, consensus recommendations were developed
for healthcare professionals regarding the use of DOACs in patients
with cancer, with a focus on the management of patients who are at risk
of nausea and vomiting.
No comments:
Post a Comment